Open and endoscopic carpal-tunnel releases are commonly used as the definitive treatment for carpal tunnel syndrome. This ...

Both i I ntraosseous and intravenous vascular access routes are used routinely in treating patients with out-of-hospital cardiac arrest, but how one method compares with the other has been unclear.

Why would an alternative to intravenous access be sought for drug administration in cases of out-of-hospital cardiac arrest? Previous trials have explored the clinical effectiveness of medications ...

The best multimodal approach for resectable esophageal adenocarcinoma is unclear. New research findings are summarized in a short video.

The Race and Medicine collection reflects NEJM’s commitment to understanding and combating racism as a public health and human rights crisis. Our commitment to antiracism includes efforts to ...

A quantitative alcohol history should be recorded for all patients, because alcohol use contributes to many physical and mental disorders. A person-centered, nonjudgmental approach should be adopted.

Patients with human epidermal growth factor receptor 2 (HER2)–positive early breast cancer with residual invasive disease after neoadjuvant systemic therapy have a high risk of recurrence and death.

Zoledronate prevents fractures in older women when administered every 12 to 18 months, but its effects on bone density and bone turnover persist beyond 5 years. Whether infrequent zoledronate ...

New catheter materials for peripherally inserted central catheters (PICCs) may reduce the risk of device failure due to infectious, thrombotic, and catheter occlusion events. However, data from ...

An urgent health care workforce crisis is looming. In the United States, a country plagued by disparate health outcomes across its geographic regions, relative physician “deserts” (i.e ...

Welcome and thank you for considering the New England Journal of Medicine (NEJM) as a venue for your work. As the oldest continuously-published medical journal, our mission since 1812 has been to ...

Allogeneic hematopoietic stem-cell transplantation is the only curative treatment for myelofibrosis. Driver mutations are the pathophysiological hallmark of the disease, but the role of mutation ...